Skip to main content
TipRanks
Go Ultimate75% OFF

OS Therapies Incorporated (OSTX) AI Stock Analysis

273 Followers
OSTX

OS Therapies Incorporated

(NYSE MKT:OSTX)

Select Model
Rating:41Neutral
Price Target:$0.88â–¼(-4.46% Downside)
Action:reiterated
Date:11/12/26

The score is held down primarily by weak financial performance (no revenue, large losses, negative equity, and ongoing cash burn) and a clearly bearish technical trend (below key moving averages with negative MACD). Corporate events modestly offset this through added funding/runway and leadership additions, but valuation support is limited due to negative earnings and no dividend.

Positive Factors
No DebtThe absence of debt in the latest annual period and TTM reduces immediate refinancing pressure and interest obligations. That gives management more flexibility to direct available resources toward clinical development and regulatory work, although continued losses could still weaken this position over time.
Negative Factors
No Commercial RevenueThe absence of commercial revenue shows that OSTX has not yet established a sales base to fund operations or validate product-market economics. Until a candidate is approved and monetized, the company remains dependent on clinical progress, regulatory outcomes, partnerships, and external capital.

OS Therapies Incorporated (OSTX) vs. SPDR S&P 500 ETF (SPY)

-80%-60%-40%-20%0%20%40%OSTX-46.26%SPY+13.11%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$34.86M
Dividend Yield
―
Average Volume (3M)
718.51K
Price to Earnings (P/E)
-0.8
Beta (1Y)
0.38
Revenue Growth
―
EPS Growth
-30.21%
Country
US
Employees
5
Sector
General
Sector Strength
55
Industry
Biotechnology

OS Therapies Incorporated Business Overview & Revenue Model

Company Description

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an of...

How the Company Makes Money

As a clinical-stage biopharmaceutical company, OSTX’s ability to generate sustainable operating revenue is typically tied to advancing its drug candidates and monetizing them through one or more of the following mechanisms: (1) out-licensing or partn...

OS Therapies Incorporated Financial Statement Overview

Summary

Financials reflect an early-stage biotech with no revenue, expanding losses, and persistent negative operating and free cash flow. While the most recent periods show no debt (a stabilizer), negative stockholders’ equity and ongoing cash burn increase funding risk and limit flexibility.

Income Statement

5Very Negative

Balance Sheet

12Very Negative

Cash Flow

8Very Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue000000
Gross Profit-374.81K-363.08K-2,780-4,220-805-1.16M
EBITDA-38.74M-28.39M-6.83M-4.34M-4.45M-4.84M
Net Income-39.37M-28.75M-8.88M-7.79M-6.25M-7.42M
Balance Sheet
Total Assets9.90B6.84M5.54M798.08K509.11K325.89K
Cash, Cash Equivalents and Short-Term Investments205.03M269.83K5.53M38.98K171.48K80.79K
Total Debt00014.61M10.35M7.07M
Total Liabilities20.74B12.94M4.73M24.81M18.07M11.78M
Stockholders Equity-11.91B-6.10M811.49K-24.02M-17.56M-11.45M
Cash Flow
Free Cash Flow-18.53M-14.24M-7.28M-3.01M-3.79M-4.41M
Operating Cash Flow-18.53M-14.24M-7.28M-3.01M-3.79M-4.40M
Investing Cash Flow0-466.42K01,145230.88K200.47K
Financing Cash Flow15.94M9.44M12.78M2.87M3.65M3.05M

OS Therapies Incorporated Technical Analysis

Technical Analysis SentimentNegative
Last Price0.92

Price Trends

50DMA1.39Negative
100DMA1.51Negative
200DMA1.53Negative

Market Momentum

MACD-0.19Positive
RSI22.27Positive
STOCH24.42Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OSTX, the sentiment is Negative. The current price of 0.92 is below the 20-day moving average (MA) of 1.05, below the 50-day MA of 1.39, and below the 200-day MA of 1.53, indicating a bearish trend. The MACD of -0.19 indicates Positive momentum. The RSI at 22.27 is Positive, neither overbought nor oversold. The STOCH value of 24.42 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OSTX.

OS Therapies Incorporated Risk Analysis

OS Therapies Incorporated disclosed 66 risk factors in its most recent earnings report. OS Therapies Incorporated reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.Our substantial indebtedness and limited cash resources could adversely affect our financial condition and ability to obtain additional financing, and a default under our Secured Notes could result in the loss of substantially all of our assets.Q2, 2026
2.The terms of our Secured Notes impose significant restrictions on our operations and financing activities, which could limit our financial and operational flexibility.Q2, 2026
3.An event of default under our Secured Notes could result in acceleration of our obligations and materially adversely affect our financial condition.Q2, 2026

OS Therapies Incorporated Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

OSTX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
ACETACET54Neutral$26.03M-0.29-69.71%――57.60%
ACRVACRV52Neutral$66.94M-0.85-80.87%――14.08%
IBIOIBIO43Neutral$52.71M-3.04-46.75%―115.00%71.61%
OSTXOSTX41Neutral$38.95M-0.831.61%――-30.21%
ELTXELTX39Underperform$45.01M-0.87-529.69%――46.62%

* General Sector Average

Performance Comparison

0%100%200%OSTXIBIOXBITACETELTXACRVDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
OSTX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
OSTXOS Therapies Incorporated0.92-0.70-43.27%
IBIOIbio Inc0.85-0.15-14.77%
XBITXBiotech Inc.1.73-0.49-22.07%
ACETAdicet Bio Inc2.50-6.74-72.94%
ELTXElicio Therapeutics, Inc1.59-6.40-80.10%
ACRVAcrivon Therapeutics, Inc.1.56-0.70-30.97%

OS Therapies Incorporated Corporate Events

Financial DisclosuresRegulatory Filings and Compliance

OS Therapies Notes FDA CNPV Program Suspension

Positive
Nov 12, 2026

OS Therapies Incorporated’s wholly owned OS Therapies UK Ltd. subsidiary is advancing Herlystic® (OST-HER2), its leading product candidate for prevention or delay of recurrence in fully resected, pulmonary metastatic osteosarcoma.On November 11, 2026...

Business Operations and StrategyPrivate Placements and Financing

OS Therapies Announces Warrant Offer to Extend Runway

Positive
Oct 19, 2026

On October 11, 2026, OS Therapies Inc. launched a warrant exercise inducement and exchange offer to a small group of accredited investors, reducing existing warrant exercise prices and issuing equal-sized new five-year warrants at $1.40 per share. Th...

Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures

OS Therapies bolsters leadership team amid commercialization push

Positive
Oct 5, 2026

Effective September 29, 2026, OS Therapies appointed Francis (Frank) Knuettel II as chief financial officer and Kerry Clem as chief commercial officer, strengthening its executive bench as it transitions from development-stage to commercialization.Th...

Business Operations and StrategyRegulatory Filings and Compliance

OS Therapies Announces Prospectus for Secondary Share Resales

Neutral
Sep 10, 2026

On September 10, 2026, OS Therapies Incorporated filed a prospectus supplement with the U.S. Securities and Exchange Commission under its effective Form S-3 shelf registration, covering the potential resale from time to time of up to 5,874,094 shares...

Executive/Board ChangesShareholder Meetings

OS Therapies Stockholders Approve Incentive Plan and Board

Positive
Sep 9, 2026

On September 9, 2026, OS Therapies Incorporated stockholders approved an amendment and restatement of the company’s 2023 Incentive Compensation Plan at the 2026 annual meeting, reinforcing its ability to grant equity‑based awards to employees and dir...

Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance

OS Therapies Launches $75 Million At-The-Market Offering

Positive
Aug 21, 2026

On August 21, 2026, OS Therapies Incorporated entered into an Open Market Sale Agreement with Jefferies LLC to establish an at-the-market equity offering program, allowing the company to sell up to $75 million of its common stock from time to time th...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 12, 2026